蔗糖铁注射液治疗维持性血液透析患者肾性贫血的疗效与安全性观察

The efficacy and safety of intravenous iron sucrose in the treatment of anemia in maintenance hemodialysis patients

目的比较静脉应用蔗糖铁(简称静脉组)与口服多糖铁复合物(简称口服组)治疗使用促红细胞生成素(EPO)的维持性血液透析(MHD)患者肾性贫血的疗效与安全性。方法采用同期随机对照研究。结果治疗后血红蛋白(Hb)、血细胞比容(HCT)、血清铁蛋白(SF)、血清转铁蛋白饱和度(TSAT)两组均有升高,静脉组比口服组升高差异有统计学意义(P<0.05),且上升速度快于口服组;静脉组不良反应少于口服组(P<0.05);治疗前后两组肝功能、C反应蛋白(CRP)等生化指标差异无统计学意义。结论静脉用蔗糖铁治疗MHD患者的肾性贫血安全有效。

Objective To determine and compare the efficacy and safety of intravenous iron sucrose（abbreviated as：iv group） with that of oral polysaccharide iron complex （ abbreviated as： oral group） in maintenance hemodialysis patients treated with rHuEPO. Methods This is a randomized controlled clinical study.Results Forty patients were divided into 2 groups：20 in iv group and 20 in oral group. All the baseline characteristics were comparable between the two groups. At the end of the trial , the hemoglobin（ Hb ）, hemotecrit（HCT） ,serum ferritin（ SF）, transferrin saturafion（TSAT） were significantly increased in both groups while the increment of above parameters in iv group was significantly higher than that in oral group（ P 〈 0.05）.There were less adverse effects in iv group than in oral group（ P 〈0.05）.The liver function and CRP between the two groups anti-or post-treatment were comparable. Conclusions Intravenous iron sucrose is effective and safe in treating anemic hemodialysis patients.